• 1
    Hepatitis B. World Health Organisation (WHO) publications, WHO/CDS/C5R/LYO/2002. 2:Hepatitis B (
  • 2
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24 (Suppl. 1): 1721.
  • 3
    Chen C-J, Yang H, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum HBV DNA level. JAMA 2006; 295: 6573.
  • 4
    Iloeje U, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678686.
  • 5
    Liaw Y-F, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 2004; 351: 15211531.
  • 6
    Li SC, Ong SC, Lim SG et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004; 38: S136S143.
  • 7
    Liaw Y-F, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489.
  • 8
    Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005; 12: 333345.
  • 9
    Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679693.
  • 10
    Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687696.
  • 11
    Marcellin P, Chang TT, Lin S et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. Hepatology 2004; 40 (Suppl. 1): 655A.
  • 12
    Kobelt G. Cost utility analysis. In: Health economics - an introduction to economic evaluation. London: Office of Health Economics, 1996: 2125.
  • 13
    Towse A. What is NICE's threshold? An external view, chapter 2. In: DevlinN, TowseA, eds. Cost-effectiveness Thresholds: Economic and Ethical Issues. London: King's Fund/Office for Health Economics, 2002: 2530.
  • 14
    Ngee WS. Purchasing Power Parity (PPP): The International Comparison Program (ICP). Statistics Singapore Newsletter, 2004: 3–6 (
  • 15
    Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409427.
  • 16
    Crowley S, Tognarini D, Desmond P et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153164.
  • 17
    Lau GKK, Priatvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 18
    Marcellin P, Gedorge KKL, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 19
    Lin X, Robinson NJ, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005; 20: 833843.
  • 20
    Kanwal F, Gralnek IM, Martin P et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Annals Intern Med 2005; 142: 821831.
  • 21
    Weitzman G, Jacobson I. Cost-effectiveness in hepatitis B. Annals Intern Med 2005; 142: 757758.
  • 22
    Sullivan SD, Veenstra DL, Chen P-E et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol 2006; Available Online.
  • 23
    De Francis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl. 1): S325.
  • 24
    Lau G, Piratvisuth T, Luo K et al. Durability of response and occurrence of late response to peginterferon alpha-2a (40 kd) [one year post-treatment in patients with HBeAg-positive chronic hepatitis]. J Hepatol 2006; 44: S23.
  • 25
    Marcellin P, Bonino F, Lau G et al. The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40 kd) sustain responses 2 years post-treatment. J Hepatol 2006; 44: S275.
  • 26
    Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748755.
  • 27
    Chang TT, Shiffman M, Tong M et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB). J Hepatol 2004; 40 (Suppl. 1): 126.
  • 28
    Singapore Life Tables. WHO Statistical Information System (WHOSIS), Life Tables for WHO member states ( WHO, 2001.
  • 29
    Perrillo RP, Lai C-L, Liaw Y-F et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186194.
  • 30
    Marcellin P, Chang TT, Lim SG et al. Baseline ALT predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV). J Hepatol 2002; 36 (Suppl. 1): 122123.
  • 31
    Locarnini S, Qi X, Arterburn S et al. Incidence of predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). Hepatology 2005; 42 (Suppl. 2): 17.
  • 32
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800807.
  • 33
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term treatment with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 26732681.